Johnson & Johnson (NYSE:JNJ) Shares Unloaded Rep. Pete Sessions

Representative Pete Sessions (R-Texas) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on June 21st, the Representative disclosed that they had sold between $15,001 and $50,000 in Johnson & Johnson stock on June 12th. The trade occurred in the Representative's "TRUST ONE" account.

Representative Pete Sessions also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of Danaher NYSE: DHR on 6/12/2025.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE JNJ traded up $0.67 during mid-day trading on Friday, hitting $163.65. The company had a trading volume of 9,764,459 shares, compared to its average volume of 8,141,137. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The company has a market capitalization of $393.75 billion, a PE ratio of 17.50, a price-to-earnings-growth ratio of 2.19 and a beta of 0.41. The business's 50-day simple moving average is $154.29 and its 200 day simple moving average is $154.97.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 EPS. The company's revenue was up 5.8% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Institutional Trading of Johnson & Johnson

Hedge funds and other institutional investors have recently modified their holdings of the business. EWA LLC boosted its position in Johnson & Johnson by 26.8% during the 2nd quarter. EWA LLC now owns 2,860 shares of the company's stock valued at $437,000 after buying an additional 604 shares during the period. Philip James Wealth Mangement LLC lifted its position in Johnson & Johnson by 13.5% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 87,853 shares of the company's stock valued at $13,420,000 after acquiring an additional 10,438 shares during the period. Gold Investment Management Ltd. increased its stake in Johnson & Johnson by 1.5% during the 2nd quarter. Gold Investment Management Ltd. now owns 18,790 shares of the company's stock valued at $2,914,000 after purchasing an additional 279 shares in the last quarter. Naples Global Advisors LLC increased its stake in Johnson & Johnson by 3.5% during the 2nd quarter. Naples Global Advisors LLC now owns 48,414 shares of the company's stock valued at $7,395,000 after purchasing an additional 1,655 shares in the last quarter. Finally, Pure Financial Advisors LLC increased its stake in Johnson & Johnson by 40.9% during the 2nd quarter. Pure Financial Advisors LLC now owns 28,037 shares of the company's stock valued at $4,283,000 after purchasing an additional 8,140 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Barclays raised their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $172.87.

About Representative Sessions

Pete Sessions (Republican Party) is a member of the U.S. House, representing Texas' 17th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Sessions (Republican Party) ran for re-election to the U.S. House to represent Texas' 17th Congressional District. He won in the general election on November 5, 2024. On October 20, 2023, Sessions announced he was running to replace Kevin McCarthy (R) as speaker of the U.S. House in the 118th Congress. Sessions lost the first round of nomination voting on October 24, 2023. Pete Sessions was born and lives in Waco, Texas. Sessions earned a B.S. from Southwestern University in 1978. Sessions' career experience includes working as an executive with AT&T.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.